Scarica l'app Stockscreener
205.37
0.36%
0.605
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
6,649 Shares in AstraZeneca PLC $AZN Acquired by Westover Capital Advisors LLC - MarketBeat
Here’s What Lifted AstraZeneca PLC (AZN) in Q4 - Insider Monkey
Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca - Benzinga
Kangtai Drops Plan for China Vaccine JV With AstraZeneca - Citeline News & Insights
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's What Happened - MarketBeat
China charges former AstraZeneca regional head Leon Wang - marketscreener.com
AstraZeneca (AZN) Faces Legal Challenges in China - GuruFocus
NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review - Benzinga
Former AstraZeneca regional head charged in China (AZN:NYSE) - Seeking Alpha
AstraZeneca And Daiichi Sankyo Stack The Odds For Datroway’s Lung Cancer Bets - Citeline News & Insights
How AstraZeneca shot for the moon — and hit - Financial Times
China charges former AstraZeneca executive Leon Wang - marketscreener.com
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
AstraZeneca's ex-chief in China formally charged with insurance fraud - The Edge Malaysia
Chinese Authorities Charge AstraZeneca's Ex-China Business Head - marketscreener.com
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline - Yahoo Finance UK
AstraZeneca PLC (NYSE:AZN) Q4 2025 Earnings Call Transcript - Insider Monkey
$3.4M for 47 local groups tackling care gaps, nutrition and lung disease - Stock Titan
China charges former AstraZeneca executive - Financial Times
AstraZeneca PLC (NYSE:AZN) Q4 2025 earnings call transcript - MSN
What's Driving the Market Sentiment Around AstraZeneca PLC? - Benzinga
AstraZeneca PLC (NASDAQ:AZN) Sees Significant Drop in Short Interest - MarketBeat
AstraZeneca PLC $AZN Holdings Boosted by ABC Arbitrage SA - MarketBeat
AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials - Clinical Trials Arena
Astrazeneca re-doses $80bn annual sales goal - marketscreener.com
AstraZeneca stock hits all-time high at 194.18 USD By Investing.com - Investing.com Nigeria
AstraZeneca Earnings Call Highlights Growth And Pipeline - TipRanks
AstraZeneca Q4 Earnings Call Highlights - Yahoo Finance
AstraZeneca: Q4 Earnings AnalysisTicks The Boxes, Upgrading To Buy (AZN) - Seeking Alpha
AstraZeneca Q4 and FY 2025 slides: 8% revenue growth, strategic investments for 2030 By Investing.com - Investing.com South Africa
AstraZeneca's GLP-1 pill succeeds in two mid-stage trials - TechTarget
AstraZeneca Unit Settles Soliris Feud With Samsung, Amgen - Law360
AstraZeneca PLC (NASDAQ:AZN) Announces Dividend of 1.60 - MarketBeat
AstraZeneca Keeps Its Growth Engine Moving Amid Rising Costs - Kalkine Media
Market Voices: Paramount-WBD bid, Holtec IPO, AstraZeneca - Seeking Alpha
Why Is AstraZeneca Stock Gaining Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
Relaxin unrest after Astrazeneca phase II HF bid joins failures - BioWorld MedTech
AstraZeneca (AZN) Surpasses Q4 Earnings Expectations, Driven by Oncology Growth - GuruFocus
Jim Cramer on AstraZeneca: “We want every drug stock” - MSN
Oakmark International Strategy Updates Portfolio, Adds AstraZene - GuruFocus
AstraZeneca bets on continued oncology demand for 2026 growth - Pharmaceutical Technology
Jim Cramer on AstraZeneca: "We Want Every Drug Stock" - Finviz
Jim Cramer on AstraZeneca: “We Want Every Drug Stock” - Insider Monkey
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity - Citeline News & Insights
AstraZeneca profits boosted by strong cancer drug sales - Investors' Chronicle
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026 - FinancialContent
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook - TradingView
AstraZeneca stock hits all-time high at 194.18 USD - Investing.com
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings - Yahoo Finance
AstraZeneca PLC $AZN Shares Purchased by Wesbanco Bank Inc. - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Foresight Group Ltd Liability Partnership - MarketBeat
Oppenheimer Asset Management Inc. Increases Position in AstraZeneca PLC $AZN - MarketBeat
Earnings call transcript: AstraZeneca’s Q4 2025 revenue grows 8%, stock rises - Investing.com
AstraZeneca Targets Global Obesity Market With Low-Cost Weight-Loss Drugs - Bloomberg
AstraZeneca (AZN) Exceeds Revenue Expectations with Strong Growt - GuruFocus
Earnings snapshot: AstraZeneca beats Q4 revenue estimates; initiates FY outlook - MSN
ProShare Advisors LLC Has $50.24 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca rises as cancer drugs power Q4 beat (AZN:NYSE) - Seeking Alpha
AstraZeneca forecasts steady growth in 2026 on cancer drug demand, hikes dividend - The Globe and Mail
AstraZeneca (AZN) Projects Revenue Growth and Core Tax Rate Outl - GuruFocus
AstraZeneca Upbeat on Growth as 2025 Profit, Revenue Rise Amid 'Excellent' Pipeline Delivery - Yahoo Finance UK
AstraZeneca’s growth engine stays on track despite cost pressures - Yahoo Finance
AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 -- Update - marketscreener.com
1.05%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):